Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered Tcells, alone or in combination with other agents, in Participants with Advanced Tumors

Grants and Contracts Details

StatusActive
Effective start/end date10/29/2010/12/24

Funding

  • PPD Investigator Services LLC: $91,251.00